These kits are manufactured in accordance with the 98/79 EC directive for in vitro diagnostic devices. Only CE marked products can be used for diagnostic applications in Europe.
These kits are intended for in vitro diagnostic use.
These kits are for research use only and are not intended to be used for diagnostic procedures.
Federal Drug Administration, FDA validates diagnostic kits for in vitro diagnostic use in the United States.
Biological risk products.
Storage between 2 and 8 ° C.
Reactive in liquid form.
Reactive in lyophilized form.
Reactive in frozen form.
Stability after opening at 2-8 ° C.
Products that can be refrozen.
Stability 12 months after refreezing at -20 ° C.
Mixture of highly purified phospholipids for dilution.
1 x 25 mg
Price list, safety data sheets and notices are accessible to our registered customers.
Phospholipids constitute a catalytic surface for the enzymatic activation of coagulation factors. Lupus circulating anticoagulants are heterogeneous autoantibodies of the IgG and IgM type directly directed against a variety of anionic phospholipids such as cardiolipin, phosphatidylserine or phosphatidylinositol or against proteins having the capacity to bind to phospholipids such as β2-glycoprotein I (β2 -GPI).
The contribution of phospholipids (PL) does not modify the levels of factors VIII, IX, XI, XII on normal plasmas without deficit nor LA. The contribution of PL does not modify the levels of factors VIII, IX, XI, XII on the known deficient plasmas with and without LA (isolated constitutional or acquired deficiency)
The supply of PL leads to an increase in factors VIII, IX, XI, XII in plasmas with LA.
Proportion of dioleoyl phosphatidyl serine: dioleoyl phosphatidyl choline (DOPS : DOPC) = 3 : 7.
Much higher activity and better reproducibility than brain phospholipids.